Nuvation Bio Inc. (NUVB) Financial Statements
Nuvation Bio Inc. (NUVB) reported trailing twelve-month revenue of $169.9M (up 1083.6% year on year) and net income of -$149.8M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$128.9M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NUVBNuvation Bio Inc.Follow NUVB — free
—
Price chart with a free account
- Market cap
- 1.6B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Revenue | 7.9 | 62.9 | 169.9 | |
| Gross profit | 0.8 | — | — | |
| Research & development | 99.1 | 115.1 | 128.9 | |
| Operating income | -592.6 | -213.1 | -137.6 | |
| Pre-tax income | -567.9 | -204.6 | -149.8 | |
| Income tax | 0.0 | 0.0 | 0.0 | |
| Net income | -567.9 | -204.6 | -149.8 | |
| Diluted EPS ($) | -2.11 | -0.60 | -0.44 | |
| Diluted shares (mn) | 268.8 | 341.5 | — |
USD millions · SEC XBRL
Nuvation Bio Inc. — questions
- What is Nuvation Bio Inc.'s revenue?
- $169.9M over the twelve months to 2026-06-30, up 1083.6% year on year, from its 10-Q and 10-K filings.
- What is Nuvation Bio Inc.'s net income?
- -$149.8M over the twelve months to 2026-06-30.
- What is Nuvation Bio Inc.'s free cash flow?
- -$128.9M over the twelve months to 2026-06-30.
- What are Nuvation Bio Inc.'s diluted earnings per share?
- $-0.44 over the twelve months to 2026-06-30.
Every figure on this page comes from Nuvation Bio Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.